Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Pancreatic acinar cell carcinoma (pACC) resection offers favorable survival, even with metastatic disease. Common homologous recombination repair (HRR) pathway mutations suggest potential targeted therapies for pACC patients.
Area Of Science
- Oncology
- Surgical Oncology
- Genetics
Background
- Pancreatic acinar cell carcinoma (pACC) is a rare pancreatic cancer with limited data on its characteristics and outcomes.
- This study aims to elucidate the clinical features, genetic landscape, and survival of patients with resected pACC.
Purpose Of The Study
- To describe the clinical characteristics of resected pancreatic acinar cell carcinoma.
- To analyze genetic alterations in pACC.
- To evaluate survival outcomes for patients with resected pACC.
Main Methods
- Retrospective analysis of 61 patients with pathologically confirmed pACC who underwent pancreatectomy across three centers (1999-2022).
- Data collected included demographics, tumor characteristics, treatment, and genetic sequencing.
- Focus on homologous recombination repair (HRR) pathway gene mutations and tumor mutational burden.
Main Results
- Median overall survival (OS) was 73 months; median recurrence-free survival was 22 months.
- Resection for oligometastatic disease showed favorable outcomes with median OS not reached.
- Homologous recombination repair (HRR) pathway gene mutations (BRCA1, BRCA2, PALB2) found in 26% of patients; 45% had other DNA damage repair gene mutations.
Conclusions
- Surgical resection of pACC is linked to favorable survival, including in oligometastatic cases.
- Frequent HRR pathway mutations in pACC present opportunities for targeted therapy development.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.